Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecompany207557-35-5 98%
(S)-1-(2-Chloroacetyl)-2-cyanopyrrolidine
(S)-1-(2-Chloroacetyl)-2-cyanopyrrolidine
(S)-1-(2-Chloroacetyl)-2-cyanopyrrolidine

207557-35-5 98%

Price Get Latest Price
Packge 1MT1kg5kg10kg25kg
  • Min. Order:1MT
  • Time:2024-03-06

Product Details

  • Product Name(S)-1-(2-Chloroacetyl)-2-cyanopyrrolidine
  • CAS No.207557-35-5
  • EINECS No.807-388-8
  • MFC7H9ClN2O
  • MW172.61
  • AppearanceSolidPale Yellow to Light Brown
  • Melting point 52-53 °C
  • Boiling point 363.1±37.0 °C(Predicted)
  • density 1.27±0.1 g/cm3(Predicted)
  • storage temp. under inert gas (nitrogen or Argon) at 2-8°C

Company Profile Introduction

Suntril Pharmaceuticals Pvt. Ltd. is a private limited company incorporated in India on 29 November 2013 and located in Chandigarh, India. The Company is engaged in the business of manufacturing in the pharmaceutical industry, particularly in the production of speciality pharmaceuticals such as Tigecycline and Strontium ranelate etc.Suntril Pharmaceuticals Pvt Ltd is committed to be a major pharmaceutical company in the field of APIs (Active Pharmaceutical Ingredients), particularly particularly in the field of oncology and non-beta-lactam drugs.

The company's products include pharmaceutical tablets, Deferasirox tablets, anti-infective APIs, tigecycline APIs, pharmaceutical raw materials and ingredients, chemical intermediates, triethylamine, APIs (Active Pharmaceutical Ingredients), Strontium Ranelate APIs, medicines for common ailments, etc. Suntril Pharmaceuticals Pvt Ltd has a strong research and development background and has the ability to develop technology for any API and expects to be a key player in the API industry.

  • Since:2021-03-01
  • Address: Plot No. 219, Phase 1 HSIIDC, Village Alipur, Teh. Barwala, Panchkula, Haryana-134118, India.
INQUIRY